Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Sotigalimab · APX-005M, CD40

Monoclonal antibody · Agonist of CD40 · developed by Apexigen America

Phase 1/2 Most advanced trial (none active)
3 Registered trials

What is Sotigalimab?

Sotigalimab is a humanized monoclonal antibody that agonizes CD40, a TNF receptor superfamily member expressed on immune cells and some cancer cells. It mimics the endogenous CD40 ligand to activate antigen-presenting cells, B cells and T cells, and can also trigger apoptosis in CD40-expressing solid tumor cells. It is being studied in melanoma, glioblastoma and other CNS tumors, and pancreatic cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
APX-005M, CD40, APX-005
Drug type
Monoclonal antibody
Targets
CD40
Mechanism
Agonist of CD40
Pathways
apoptosis, antigen-presenting cell activation, B-cell activation, T-cell activation
Therapy area
Oncology
Developer
Apexigen America, Inc.
In trials of
PYXS, RCUS
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
JEA93WJ5DG

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05419479 Phase 1/2 Pancreatic Cancer Suspended RCUS
NCT02706353 Phase 1/2 Melanoma Terminated PYXS
NCT03389802 Phase 1 Glioblastoma Multiforme Completed PYXS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Adenocarcinoma of the PancreasAdenosquamous Carcinoma of the PancreasCNS Primary Tumor, Not Otherwise Specified (NOS)Diffuse Intrinsic Pontine Gliomas (DIPG)Ependymoma, Not Otherwise Specified (NOS)Glioblastoma MultiformeHigh-grade Astrocytoma Not Otherwise Specified (NOS)MedulloblastomaMelanomaPancreatic CancerSquamous Cell Carcinoma of Pancreas

Other drugs acting on CD40

Sources

Updated Oct 25, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.